How Has the Sarcopenia Treatment Market Size Evolved in Recent Years?
The sarcopenia treatment market has seen considerable growth due to a variety of factors.
• The market for sarcopenia treatment has seen substantial growth in recent years, expanding from $3.52 billion in 2024 to an estimated $3.73 billion in 2025.
This increase, corresponding to a compound annual growth rate (CAGR) of 6.1%, has been driven by several factors including an aging population, enhanced awareness and diagnosis, changes in lifestyle, public health campaigns, and regulatory endorsements.
What Are The Predictions for The Sarcopenia Treatment Market in the Coming Years?
The sarcopenia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for sarcopenia treatment is predicted to witness a substantial rise in the coming years, reaching $4.72 billion by 2029, a projection based on a 6.0% compound annual growth rate (CAGR). The surge in this period is tied to factors such as personalized medicine, dietary alterations, the use of digital health platforms, patient awareness and empowerment, as well as global health movements. The period's key trends will likely revolve around custom therapies, the development of new drug categories, the incorporation of digital health, cooperative research projects, and research and development.
Which Drivers Are Accelerating Growth In The Sarcopenia Treatment Market?
The escalation in malnutrition rates is anticipated to be a significant driving force behind the growth of the sarcopenia treatment market. Malnutrition is characterized by deficiencies, overconsumption, or imbalances in a person's consumption of energy and nutrients, encompassing undernourishment, obesity, and diet-related noncommunicable diseases. Sarcopenia treatments aim to combat the concurrent conditions of malnutrition and sarcopenia in elderly individuals via tactics such as nutritional therapy and fitness, targeting the enhancement of muscle mass, strength, and comprehensive nutritional status. For example, a report released by the World Health Organization (WHO), a UN organization headquartered in Switzerland, in December 2023, asserted that malnutrition continues to be a global health concern, reporting an estimated 462 million underweight and 149 million children under 5 who experienced stunting in 2022. Consequently, the surging malnutrition rates are propelling the expansion of the sarcopenia treatment market.
What Are The Core Segments Of The Global Sarcopenia Treatment Market?
The sarcopenia treatment market covered in this report is segmented –
1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein
2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin
3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate
4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions
Pre-Book The Sarcopenia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Sarcopenia Treatment Market?
Top firms involved in the sarcopenia treatment market are escalating their emphasis on developing an array of advanced clinical options to improve treatment choices. A clinical study is a methodical research conducted on people to appraise the safety, effectiveness, and resulting impact of a medical intervention. For example, in September 2023, French biotech firm, Biophytis received approval from the Food and Drug Administration (FDA) to start the SARA-31 Phase 3 study in sarcopenia. This study will evaluate the safety and effectiveness of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of motor disability. The study marks a significant advancement in technology and drug treatment methods, providing potential safety and effectiveness benefits for severe sarcopenic patients. Marking its debut as a phase 3 study in sarcopenia, it has gained FDA's approval. The study will involve approximately 900 patients aged above 65 with sarcopenia, low pace of walking and reduced hand grip strength. The study's principal aim will be to evaluate the risk of major mobility disability (MMD), walking speed, hand grip strength and the patient-reported quality of life.
Who Are the Key Players In The Sarcopenia Treatment Market?
Major companies operating in the sarcopenia treatment market report are:
• Pfizer Inc.
• F-Hoffmann La-Roche
• Merck Sharp & Dohme Corp. (Merck & Co.)
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• BASF SE
• Nestle Health Science
• Haleon Group of Companies
• Regeneron Pharmaceuticals Inc.
• DSM
• American Way (Amway) Corporation
• Perrigo Company PLC
• Intas Pharmaceuticals Ltd
• Zydus Lifesciences
• Fermenta Biotech Limited
• Metagenics LLC
• Ion Labs Inc.
• Makers Nutrition LLC
• NutraScience Labs
• AstaReal AB
• NutraPak USA
• BioThrive Sciences
• Wellona Pharma
• Healing Pharma India Pvt. Ltd.
• Nutrafill
What Are The Regional Insights Into The Sarcopenia Treatment Market?
North America was the largest region in the sarcopenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
